MX2024004429A - Regimenes de dosificacion del anticuerpo anti-ctla-4. - Google Patents
Regimenes de dosificacion del anticuerpo anti-ctla-4.Info
- Publication number
- MX2024004429A MX2024004429A MX2024004429A MX2024004429A MX2024004429A MX 2024004429 A MX2024004429 A MX 2024004429A MX 2024004429 A MX2024004429 A MX 2024004429A MX 2024004429 A MX2024004429 A MX 2024004429A MX 2024004429 A MX2024004429 A MX 2024004429A
- Authority
- MX
- Mexico
- Prior art keywords
- ctla
- dosing regimens
- antibody dosing
- antibody
- regimens
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Oncology (AREA)
- Dermatology (AREA)
- Epidemiology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163273660P | 2021-10-29 | 2021-10-29 | |
| PCT/US2022/078875 WO2023077069A1 (en) | 2021-10-29 | 2022-10-28 | Anti-ctla-4 antibody dosing regimens |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2024004429A true MX2024004429A (es) | 2024-05-06 |
Family
ID=86158833
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2024004429A MX2024004429A (es) | 2021-10-29 | 2022-10-28 | Regimenes de dosificacion del anticuerpo anti-ctla-4. |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20260139052A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4422685A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2024540152A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20240099187A (cg-RX-API-DMAC7.html) |
| CN (1) | CN118176021A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2022377644A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3234351A1 (cg-RX-API-DMAC7.html) |
| MX (1) | MX2024004429A (cg-RX-API-DMAC7.html) |
| TW (1) | TW202325738A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2023077069A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2024238912A1 (en) * | 2023-05-17 | 2024-11-21 | OncoC4, Inc. | Ph-sensitive anti-ctla-4 antibodies and uses thereof |
| WO2026041780A2 (en) * | 2024-08-23 | 2026-02-26 | BioNTech SE | Combination therapy comprising anti-ctla4 antibodies and chemotherapy for cancer treatment |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ568016A (en) * | 2005-12-07 | 2011-12-22 | Medarex Inc | CTLA-4 antibody dosage escalation regimens |
| EP2912063A1 (en) * | 2012-10-23 | 2015-09-02 | Bristol-Myers Squibb Company | Combination of anti-kir and anti-ctla-4 antibodies to treat cancer |
| LT3142751T (lt) * | 2014-05-13 | 2019-09-25 | Medimmune Limited | Anti-b7-h1 ir anti-ctla-4 antikūnai nesmulkialąstelinio plaučių vėžio gydymui |
| AU2016370648B2 (en) | 2015-12-15 | 2023-03-09 | OncoC4, Inc. | Chimeric and humanized anti-human CTLA4 monoclonal antibodies and uses thereof |
| TWI799432B (zh) * | 2017-07-27 | 2023-04-21 | 美商再生元醫藥公司 | 抗ctla-4抗體及其用途 |
| CN119792515A (zh) * | 2018-02-13 | 2025-04-11 | 默沙东有限责任公司 | 用抗pd-1抗体和抗ctla-4抗体治疗癌症的方法 |
-
2022
- 2022-10-28 MX MX2024004429A patent/MX2024004429A/es unknown
- 2022-10-28 JP JP2024525557A patent/JP2024540152A/ja active Pending
- 2022-10-28 CN CN202280072636.XA patent/CN118176021A/zh active Pending
- 2022-10-28 US US18/705,924 patent/US20260139052A1/en active Pending
- 2022-10-28 AU AU2022377644A patent/AU2022377644A1/en active Pending
- 2022-10-28 WO PCT/US2022/078875 patent/WO2023077069A1/en not_active Ceased
- 2022-10-28 CA CA3234351A patent/CA3234351A1/en active Pending
- 2022-10-28 EP EP22888534.9A patent/EP4422685A4/en active Pending
- 2022-10-28 TW TW111141150A patent/TW202325738A/zh unknown
- 2022-10-28 KR KR1020247012748A patent/KR20240099187A/ko active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2024540152A (ja) | 2024-10-31 |
| EP4422685A1 (en) | 2024-09-04 |
| TW202325738A (zh) | 2023-07-01 |
| WO2023077069A1 (en) | 2023-05-04 |
| AU2022377644A1 (en) | 2024-05-16 |
| US20260139052A1 (en) | 2026-05-21 |
| EP4422685A4 (en) | 2025-12-03 |
| KR20240099187A (ko) | 2024-06-28 |
| CN118176021A (zh) | 2024-06-11 |
| CA3234351A1 (en) | 2023-05-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2020006668A (es) | Anticuerpos para lilrb2. | |
| PH12021550152A1 (en) | Anti-cd112r compositions and methods | |
| MX2020012797A (es) | Anticuerpos biespecificos anti-pvrig/anti-tigit y métodos de uso. | |
| MX2025002661A (es) | Composiciones anti-cd24 y usos de las mismas | |
| MX2024007724A (es) | Conjugados de farmaco-anticuerpo anti-antigeno de membrana especifico de prostata (psma) humanizado | |
| MX2024000614A (es) | Anticuerpos anti-fgfr2 combinados con quimioterapia para el tratamiento del cancer. | |
| MY195110A (en) | Antibodies to PD-1 and uses Thereof | |
| PH12018502112B1 (en) | Anti-tim-3 antibodies and compositions | |
| ZA202005388B (en) | Methods of treating ulcerative colitis | |
| ZA202206993B (en) | Anti-lilrb1 antibody and uses thereof | |
| EA201691824A1 (ru) | АНТИТЕЛА ПРОТИВ EGFRvIII И ИХ ПРИМЕНЕНИЯ | |
| TW201713698A (en) | PD-1 antibodies | |
| PH12016500137B1 (en) | Afucosylated anti-fgfr2iiib antibodies | |
| PH12019550233A1 (en) | A novel anti-c-met antibody and use thereof | |
| MY202870A (en) | Anti-ctla-4 antibodies and uses thereof | |
| PH12022550246A1 (en) | A dosing regimen for an ido inhibitor | |
| MX2019002728A (es) | Combinacion de un anticuerpo anti-cd20, inhibidor de quinasa pi3-delta, y anticuerpo anti-pd-1 o anti-pd-l1 para el tratamiento hematologico de los canceres. | |
| PH12020551968A1 (en) | Anti-sez6 antibody drug conjugates and methods of use | |
| MX2021005236A (es) | Regimen de dosificacion de anticuerpo anti-tigit para el tratamiento de cancer. | |
| BR112017011538A2 (pt) | combinação de anticorpos anti-cs1 e anti-pd1 para tratar câncer (mieloma) | |
| PH12019502313A1 (en) | Anti-pd-l1-anti-tim-3 bispecific antibodies | |
| MX2021010116A (es) | Anticuerpo anti-pd-l1 y uso de este. | |
| MX2023006777A (es) | Composiciones y métodos que comprenden antagonistas de proteína 2 relacionada con frizzled secretada (sfrp2). | |
| ZA202106807B (en) | Antibodies having specificity for btn2 and uses thereof | |
| EP4541423A3 (en) | Dosing regimen of avelumab for the treatment of cancer |